Stock Track | Cassava Sciences Soars on Positive Analyst Outlook for Alzheimer's Drug

Stock Track11-09

Shares of Cassava Sciences Inc. (SAVA) soared by 5.05% on Thursday, November 8th, 2024, closing at $116 per share. The surge was primarily driven by a positive analyst rating and price target from H.C. Wainwright.

H.C. Wainwright analyst Vernon Bernardino maintained a Buy rating on Cassava Sciences and set a price target of $116 for the stock. Bernardino's bullish outlook was based on the promising potential of Cassava's investigational drug simufilam as a disease-modifying treatment for Alzheimer's disease.

Cassava Sciences is currently conducting a Phase 3 clinical trial for simufilam, and positive results from this trial are expected to further boost investor confidence in the company's prospects. The analyst report highlighted simufilam's ability to target and disrupt the formation of neurotoxic proteins believed to be a root cause of Alzheimer's disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192356244?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-09 03:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192356244","market":"hk","top_or_hot":-1,"title":"Stock Track | Cassava Sciences Soars on Positive Analyst Outlook for Alzheimer's Drug","media":"Stock Track","content":"<p>Shares of Cassava Sciences Inc. (SAVA) soared by 5.05% on Thursday, November 8th, 2024, closing at $116 per share. The surge was primarily driven by a positive analyst rating and price target from H.C. Wainwright.</p>\n\n<p>H.C. Wainwright analyst Vernon Bernardino maintained a Buy rating on Cassava Sciences and set a price target of $116 for the stock. Bernardino's bullish outlook was based on the promising potential of Cassava's investigational drug simufilam as a disease-modifying treatment for Alzheimer's disease.</p>\n\n<p>Cassava Sciences is currently conducting a Phase 3 clinical trial for simufilam, and positive results from this trial are expected to further boost investor confidence in the company's prospects. The analyst report highlighted simufilam's ability to target and disrupt the formation of neurotoxic proteins believed to be a root cause of Alzheimer's disease.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Cassava Sciences Soars on Positive Analyst Outlook for Alzheimer's Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Cassava Sciences Soars on Positive Analyst Outlook for Alzheimer's Drug\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-09 03:44 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Cassava Sciences Inc. (SAVA) soared by 5.05% on Thursday, November 8th, 2024, closing at $116 per share. The surge was primarily driven by a positive analyst rating and price target from H.C...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SAVA","symbol_name":"Cassava Sciences Inc","start_time":0,"source_url":"","article_id":"1192356244","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192356244","pubTimestamp":1731095086,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Cassava Sciences Inc.  soared by 5.05% on Thursday, November 8th, 2024, closing at $116 per share. The surge was primarily driven by a positive analyst rating and price target from H.C. Wainwright.H.C. Wainwright analyst Vernon Bernardino maintained a Buy rating on Cassava Sciences and set a price target of $116 for the stock. Bernardino's bullish outlook was based on the promising potential of Cassava's investigational drug simufilam as a disease-modifying treatment for Alzheimer's di","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SAVA":"Cassava Sciences Inc"},"translate_title":"分析师对阿尔茨海默病药物前景乐观，木薯科学股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAVA":1},"content_text":"Shares of Cassava Sciences Inc. (SAVA) soared by 5.05% on Thursday, November 8th, 2024, closing at $116 per share. The surge was primarily driven by a positive analyst rating and price target from H.C. Wainwright.\nH.C. Wainwright analyst Vernon Bernardino maintained a Buy rating on Cassava Sciences and set a price target of $116 for the stock. Bernardino's bullish outlook was based on the promising potential of Cassava's investigational drug simufilam as a disease-modifying treatment for Alzheimer's disease.\nCassava Sciences is currently conducting a Phase 3 clinical trial for simufilam, and positive results from this trial are expected to further boost investor confidence in the company's prospects. The analyst report highlighted simufilam's ability to target and disrupt the formation of neurotoxic proteins believed to be a root cause of Alzheimer's disease.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192356244"}